SABCS 2022 Conference Coverage

 

SABCS 2022 Conference Coverage
S

SABCS 2022 Phase 3 TROPiCS-02 Study: Exposure-Adjusted Incidence Rates of Adverse Events of Sacituzumab Govitecan vs. Treatment of Physician’s Choice in HR+/HER2- mBC

By SABCS 2022 Conference Coverage FEATURING Sara Tolaney
By SABCS 2022 Conference Coverage FEATURING Sara Tolaney
64 views
December 19, 2022
0 Comments
Login to view comments. Click here to Login
Videos
09:01
SABCS 2022 Conference Coverage

Adjuvant Treatment for HR+/HER2-, Node-Positive, High-Risk eBC: 4-Ye…

Feat. W. Mchayleh
11:09
SABCS 2022 Conference Coverage

SABCS 2022 Results From a Pre-Planned monarchE OS Interim Analysis, …

Feat. J. Huober
22:22
SABCS 2022 Conference Coverage

SABCS 2022 Genomic Analysis of ctDNA From Patients With HR+, HER2-Mu…

Feat. C. Ma
06:10
SABCS 2022 Conference Coverage

SABCS 2022: The Effect of Race on Pathologic Complete Response Rates…

Feat. H. Woriax
12:44
SABCS 2022 Conference Coverage

SABCS 2022 Primary Results From the Randomized Phase II RIGHT Choice…

Feat. Y. Lu
06:42
SABCS 2022 Conference Coverage

SABCS 2022 Long-Term Survival of the GeparOLA Study: Neoadjuvant Pac…

Feat. P. Fasching
27:50
SABCS 2022 Conference Coverage

SABCS 2022 Beyond Anthracyclines and Trastuzumab: Cardiotoxicity of …

Feat. S. Dent
10:47
SABCS 2022 Conference Coverage

SABCS 2022 Population-Based Estimates of Contralateral BC Risk Among…

Feat. S. Yadav
04:21
SABCS 2022 Conference Coverage

SABCS 2022 on the OPHELIA Study: Olaparib + Trastuzumab in HER2+ BRC…

Feat. J. Martínez
11:09
SABCS 2022 Conference Coverage

SABCS 2022 Primary Results of the Randomized Phase 3 DESTINY-Breast0…

Feat. I. Krop
07:32
SABCS 2022 Conference Coverage

SABCS 2022 Early TNBC Treated With Neoadjuvant Chemo: Association of…

Feat. D. Krug
15:23
SABCS 2022 Conference Coverage

SABCS 2022 Primary Results From the POSITIVE Trial (IBCSG 48-14 / BI…

Feat. H. Azim
08:39
SABCS 2022 Conference Coverage

SABCS 2022 Tumor-Agnostic Measurement of ctDNA Levels With mFAST-Seq…

Feat. N. Verschoor
07:39
SABCS 2022 Conference Coverage

SABCS 2022 Post-Neoadjuvant Therapy in TNBC: To Clip or Not to Clip

Feat. V. Galimberti
13:46
SABCS 2022 Conference Coverage

SABCS 2022 TROPiCS-02 Phase 3 Study of Patients With HR+/HER2- mBC: …

Feat. H. Rugo
07:41
SABCS 2022 Conference Coverage

SABCS 2022 DETECT V Phase 3 Trial: Omission of Chemo in the Treatmen…

Feat. W. Janni
07:15
SABCS 2022 Conference Coverage

SABCS 2022: CBD Oil - A Potential Solution in Case of Severe Tamoxif…

Feat. S. Buijs
05:38
SABCS 2022 Conference Coverage

SABCS 2022: Correlating Predicted Adjuvant Therapy Benefit and Risk …

Feat. R. Patel
02:16
SABCS 2022 Conference Coverage

SABCS 2022 Phase 2 Expansion (VERITAC) of a Phase 1/2 Study: ARV-471…

Feat. E. Hamilton
10:47
SABCS 2022 Conference Coverage

SABCS 2022 Dose-Expansion Study DESTINY-Breast07: T-DXd as Monothera…

Feat. E. Hamilton
19:54
SABCS 2022 Conference Coverage

SABCS 2022 Hormonal Exposures and Cancer Risk in BRCA1/2 Mutation Ca…

Feat. J. Kotsopoulos
05:34
SABCS 2022 Conference Coverage

SABCS 2022 Identifying Drivers of 1L HR+/HER2- mBC Treatment Choices

Feat. A. Brufsky
06:45
SABCS 2022 Conference Coverage

SABCS 2022 Post Hoc Analysis of Adjuvant RT in the Phase 3 KEYNOTE-5…

Feat. H. McArthur
13:17
SABCS 2022 Conference Coverage

SABCS 2022 Post Neoadjuvant Therapy in TNBC

Feat. H. McArthur
07:30
SABCS 2022 Conference Coverage

SABCS 2022 Impact of Adjuvant ET Omission in ER+ BC Treated With Neo…

Feat. G. Choong
12:42
SABCS 2022 Conference Coverage

SABCS 2022 Multicenter Retrospective ROSET-BM Study: T-DXd for the T…

Feat. Y. Takashi
05:36
SABCS 2022 Conference Coverage

SABCS 2022 Breast Preservation After Local Recurrence of BC: Compari…

Feat. H. Kolberg
04:44
SABCS 2022 Conference Coverage

SABCS 2022 Molecular Fluorescence-Guided Surgery Using BEVA800 for t…

Feat. H. Kolberg
07:24
SABCS 2022 Conference Coverage

SABCS 2022 Comparison of a Mono Atezo Window Followed by Atezo &…

Feat. H. Kolberg
19:57
SABCS 2022 Conference Coverage

SABCS 2022 Challenging Types of Breast Cancer: Lobular/Pleomorphic

Feat. S. Loibl
05:50
SABCS 2022 Conference Coverage

SABCS 2022 PENELOPE-B and PALLAS Trials: Development and Validation …

Feat. S. Loibl
05:45
SABCS 2022 Conference Coverage

SABCS 2022 Adjuvant Paclitaxel & Trastuzumab for Node- HER2+ BC:…

Feat. S. Tolaney
02:31
SABCS 2022 Conference Coverage

SABCS 2022 Phase 3 TROPiCS-02 Study: Exposure-Adjusted Incidence Rat…

Feat. S. Tolaney
12:21
SABCS 2022 Conference Coverage

SABCS 2022 Phase 3 Randomized Controlled Trial: Addition of Platinum…

Feat. S. Gupta
10:25
SABCS 2022 Conference Coverage

SABCS 2022 Biology and Clinical Course of Lobular Cancer in BC

Feat. R. Layman
06:48
SABCS 2022 Conference Coverage

SABCS 2022: PgR Levels & Ki67 Expression of Lobular Carcinomas o…

Feat. C. Markopoulos
10:52
SABCS 2022 Conference Coverage

SABCS 2022 Patient-Reported Cognitive Impairment in Women Participat…

Feat. I. Kang
16:23
SABCS 2022 Conference Coverage

SABCS 2022 Immune Landscape and Microenvironments in BC

Feat. M. Ignatiadis
16:49
SABCS 2022 Conference Coverage

SABCS 2022 Inflammatory Breast Cancer: A Perfect Storm

Feat. F. Lynce
06:37
SABCS 2022 Conference Coverage

SABCS 2022 High PD-L2 Protein Expression in Cancer Cells Is an Indep…

Feat. L. Chaudhary
10:17
SABCS 2022 Conference Coverage

SABCS 2022 Clinical Use of Breast Cancer Index for Prediction of Lat…

Feat. V. Dabak
20:32
SABCS 2022 Conference Coverage

SABCS 2022: Enhancing the Effects of Immunotherapy in Metastatic Bre…

Feat. M. Gatti-Mays
07:48
SABCS 2022 Conference Coverage

SABCS 2022: Real-World 2L Treatment Patterns and Associated Clinical…

Feat. K. Clifton
04:32
SABCS 2022 Conference Coverage

SABCS 2022 Phase 3 TAILORx Breast Cancer Trial: 21-Gene Recurrence S…

Feat. S. Yang
11:42
SABCS 2022 Conference Coverage

SABCS 2022: Trastuzumab-Induced Tumor Microenvironment Changes in Ea…

Feat. L. Kennedy
12:00
SABCS 2022 Conference Coverage

SABCS 2022 CDK4/6 Inhibitors: Are They All the Same or Different?

Feat. D. Patt
10:01
SABCS 2022 Conference Coverage

SABCS 2022 Results of the Randomized, Multi-Dose Phase 2 SERENA-2 Tr…

Feat. M. Oliveira
10:10
SABCS 2022 Conference Coverage

SABCS 2022 Results from ACOSOG Z11102 (Alliance): Impact of Breast C…

Feat. J. Boughey
14:58
SABCS 2022 Conference Coverage

SABCS 2022 Poster Reviews of Special Populations: Male Breast Cancer

Feat. J. Pablo Leone
09:13
SABCS 2022 Conference Coverage

SABCS 2022 Predictors of Response to Neoadjuvant Chemo in Breast Can…

Feat. N. Bilani
13:17
SABCS 2022 Conference Coverage

SABCS 2022 Chemotherapy-Induced Cardio Toxicity: The Patient Experie…

Feat. A. Gaffney-Adams
12:02
SABCS 2022 Conference Coverage

SABCS 2022 10-Year Results of a Phase 3 Trial of Low-Dose Tamoxifen …

Feat. A. De Censi
14:28
SABCS 2022 Conference Coverage

SABCS 2022 EMERALD Phase 3 Trial Updated Results by Duration of Prio…

Feat. H. Khong
18:43
SABCS 2022 Conference Coverage

SABCS 2022 Antibody Drug Conjugates for TNBC

Feat. L. Ellisen
13:05
SABCS 2022 Conference Coverage

SABCS 2022 Stromal Tumor-Infiltrating Lymphocytes Identify Early-Sta…

Feat. R. Leon Ferre
12:54
SABCS 2022 Conference Coverage

SABCS 2022 Phase III SWOG S1207 Trial: Evaluating Adjuvant ET +/- 1 …

Feat. M. Mac Gregor
09:40
SABCS 2022 Conference Coverage

SABCS 2022 Updated Survival Results of the Randomized Phase 3 Study …

Feat. S. Hurvitz
08:25
SABCS 2022 Conference Coverage

SABCS 2022 Race & Clinical Outcomes in the RxPONDER Trial (SWOG …

Feat. Y. Abdou
05:53
SABCS 2022 Conference Coverage

SABCS 2022 Patient-Reported Outcomes From the TROPiCS-02 Trial: The …

Feat. F. Marmé
25:01
SABCS 2022 Conference Coverage

SABCS 2022: FLASH-RT, Ultra-High Dose Rate Rate Radiotherapy, Is as …

Feat. F. Dirbas
04:35
SABCS 2022 Conference Coverage

SABCS 2022 5-Year Results and Correlative Analyses From ATEMPT (TBCR…

Feat. P. Tarantino
03:14
SABCS 2022 Conference Coverage

SABCS 2022: Comprehensive Genomic Characterization of HER2-Low Breas…

Feat. P. Tarantino
06:54
SABCS 2022 Conference Coverage

SABCS 2022 Correlative Analysis From NeoPACT and NeoSTOP Trials: Ass…

Feat. P. Sharma
06:51
SABCS 2022 Conference Coverage

SABCS 2022: Genomic and Transcriptomic Landscape of HER2-Low Breast …

Feat. R. Bansal
10:46
SABCS 2022 Conference Coverage

SABCS 2022 on a Randomized Phase II PACE (Palbociclib After CDK4/6i …

Feat. E. Mayer
49:07
SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

Feat. J. O'Shaughnessy, S. Tolaney, S. Hurvitz, H. Rugo
08:33
SABCS 2022 Conference Coverage

SABCS 2022 Validation of Profile for the Omission of Local Adjuvant …

Feat. P. Karlsson
03:02
SABCS 2022 Conference Coverage

SABCS 2022 Clinical and Molecular Characteristics of HER2-Low/Zero E…

Feat. C. Yam
08:15
SABCS 2022 Conference Coverage

SABCS 2022 Absence of Lobular Carcinoma in Situ, a Poor Prognostic M…

Feat. J. Mouabbi